Related Experiment Video

Updated: Jun 7, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics

Yael S Barach1, Jun Sik Lee1, Xingxing Zang2

  • 1Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Trends in Molecular Medicine
|October 26, 2010
PubMed

Insights

Prostate cancer uses coinhibition to evade the immune system. Blocking B7x and B7-H3 offers a promising immunotherapy strategy, potentially enhancing traditional treatments for better outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Adaptive immunity relies on T cell costimulation and coinhibition.
  • The B7 family and CD28 family receptors mediate these interactions.
  • Prostate cancer exploits coinhibitory pathways for immune evasion.

Purpose of the Study:

  • To investigate the role of coinhibitory molecules in prostate cancer's immune evasion.
  • To explore the therapeutic potential of targeting coinhibitory B7x and B7-H3 in prostate cancer.

Main Methods:

  • Analysis of B7x, B7-H3, PD-L1, and PD-1 expression in prostate tumors.
  • Review of emerging immunotherapies targeting T cell coinhibition.

Main Results:

  • Overexpression of coinhibitory B7x and B7-H3 correlates with poor prostate cancer outcomes.
  • Tumor-infiltrating immune cells show increased PD-L1 and PD-1 expression.
  • Antagonistic monoclonal antibodies targeting coinhibition are effective immunotherapies.

Conclusions:

  • Targeting coinhibitory B7x and B7-H3 is a viable therapeutic strategy for prostate cancer.
  • Blocking these molecules may synergize with traditional therapies.
  • Further research into B7 expression mechanisms in the tumor microenvironment is warranted.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...